Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 10/20 | 0.43 |
| ▸ | SCN9A | Q15858 | 4/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.39 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.38 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.38 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.38 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | CES2 | O00748 | 1/20 | 0.38 |
| ▸ | CFTR | P13569 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3929529 | 0.91 | AKT1 (0.38) | TACR1SCN9AALDH1A1NOTUMMAPT | |
| SCHEMBL25623724 | 0.91 | AKT1 (0.38) | TACR1SCN9AALDH1A1NOTUMMAPT | |
| SCHEMBL24037031 | 0.91 | CTSA (0.38) | TACR1SCN9AALDH1A1NOTUMMAPT | |
| SCHEMBL25752836 | 0.90 | SLC13A3 (0.40) | TACR1SCN9ANOTUMMAPT | |
| SCHEMBL24037032 | 0.90 | NOTUM (0.50) | TACR1SCN9AALDH1A1NOTUMCFTR | |
| SCHEMBL24037035 | 0.90 | RXRA (0.42) | TACR1SCN9A | |
| SCHEMBL24037033 | 0.90 | TACR1 (0.36) | TACR1SCN9AALDH1A1NOTUMCACNA1F | |
| Hydrochloric Acid SCHEMBL30388827 | 0.89 | SLC13A3 (0.40) | TACR1SCN9ANOTUMMAPT | |
| SCHEMBL24036567 | 0.87 | SCN9A (0.37) | TACR1SCN9AALDH1A1NOTUMMAPT | |
| SCHEMBL19283469 | 0.85 | PNMT (0.49) | TACR1ALDH1A1CES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230192661-A1 | 1, 4, 5, 6-TETRAHYDROPYRIMIDINE-2-AMINE DERIVATIVE | UBE CORPORATION (JP) | 2023-06-22 | — | — | US | disclosed |
| WO-2023085396-A1 | PHARMACEUTICAL COMPOSITION FOR PROVIDING TREATMENT FOR OR PREVENTING ALPORT SYNDROME | ＵＢＥ株式会社 | 2023-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192661-A1 | 1, 4, 5, 6-TETRAHYDROPYRIMIDINE-2-AMINE DERIVATIVE | DHFR, DPYD, CYP2D6 | TACR1 1449/4885SCN9A 1868/4885ALDH1A1 208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.